recurrent neuroblastoma Recurrent Neuroblastoma, Liquid Biopsy, ctDNA
Conditions
Interventions
None listed
Sponsors
Nitani Chika
Kubota Hirohito
Eligibility
Inclusion criteria
Inclusion criteria: Patients with relapsed (including second or subsequent relapse) or progressive neuroblastoma with distant metastasis (regardless of initial risk classification). Registered in the Pediatric Solid Tumor Observation Study with submitted samples. Research subjects who have received a sufficient explanation of their participation in this study, have provided informed consent with sufficient understanding, either by their own free will or by a proxy with documented consent if the subject's own consent is difficult to obtain.
Exclusion criteria
Exclusion criteria: In cases where it is difficult to draw the specified amount of blood (minimum 4 ml per draw). Patients whom the principal investigator deems inappropriate for participation in the study for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gene expression and neuroblastoma-related genetic mutations at various time points. Response status at the end of 2 courses of chemotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Event-free survival (EFS) Overall survival (OS) Tumor fraction in cfDNA after relapse therapy ctDNA detection status at 12 months from the end of 2 courses of relapse therapy Concordance of genetic mutations between plasma samples and primary or relapsed tumor tissue Time from sample submission to result return | — |
Contacts
Public ContactChika Nitani
Osaka City General Hospital
Outcome results
None listed